Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVOID-AS
NCT05143177Phase 3Terminated
- Sponsor
- REDNVIA
- Start
- Jun 2022
- Primary completion
- Mar 2026
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in calcific aortic valve disease (CAVD) comparing Placebo with DA-1229 10 mg (2 arms). Primary endpoint: Aortic valve calcification as measured by change from baseline in Agatston arbitrary unit (AU) at 104 weeks. Started Jun 2022; status: terminated.
02
Drugs
DA5221-B2
03
Conditions
calcific aortic valve disease (CAVD)
Beyond the preview
Go deeper on NCT05143177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05143177.